Drug profile

The FDA adverse-event record for Psyllium Husks

14 FDA reports name Psyllium Husks, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2193 of 2,679
by report volume (all drugs)
14
adverse-event reports
7.1%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Psyllium Husks ranks #2133 of 2679 by total reports (14). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2133
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Psyllium Husks has 14 reports now versus 13 in that prior snapshot: 1 more (7.7%).

Report change
+1
Death-coded reports
+1
Death-coded share
+7.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Psyllium Husks changes

Signature read: 14 reports place Psyllium Husks in the lower third of FDA AER volume (#2193 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
1
Deaths Reported
7.1%
Death-coded share of reports

Active Ingredients

Psyllium Husks

Administration Routes

UnknownOral

Species Affected

Dog 13
Cat 1

Most Affected Breeds

Chihuahua 3
Retriever - Golden 2
Shepherd Dog - German 2
Pointing Dog - Hungarian Short-haired (Vizsla) 1
Greyhound 1
Shepherd Dog - Australian 1
Siberian Husky 1
Domestic Shorthair 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Terrier - American Staffordshire 1

Most Reported Reactions

Diarrhoea 8
Lethargy (see also Central nervous system depression in Neurological) 5
Abnormal radiograph finding 4
Thrombocytopenia 3
Neutrophilia 3
Elevated alanine aminotransferase (ALT) 3
Vomiting 3
Decreased appetite 3
Impaired hearing 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Lack of efficacy (endoparasite) - hookworm 2
Anorexia 2

Outcome Breakdown

Outcome Unknown
7 (50.0%)
Ongoing
6 (42.9%)
Euthanized
1 (7.1%)

Psyllium Husks: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Psyllium Husks (#2193 of 2,679 by report volume); death-coded 7.1%. PlainBreed drug row · report volume stamp 14 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →